Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer

Gene expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last decade, 4 intrinsic molecular subtypes of breast cancer (Lumina! A, Luminal B, HER2-enriched [HER2-E] and Basal-like) have been identified and intensively studied. In this article, we review and discuss the clinical implications of the 2 non-luminal subtypes (i.e. HER2-E and Basal-like) identified within hormone receptor (HR)-positive disease. After reviewing 32 studies for a total of 13,091 samples, similar to 8% and similar to 15% of early and metastatic HR +/HER2-negative breast cancer, respectively, were found to be non-luminal. Clinically, HR + /HER2-negative/non-luminal subtypes have been associated with estrogen independence, chemo-sensitivity, resistance to CDK4/6 inhibition and poor outcome. Interestingly, EGFR/HER2 tyrosine kinase inhibition might be of value in the HR+/HER2-negative/HER2-E subtype. Finally, the HER2-E subtype within HR + /HER2 + disease represents similar to 30% and has been associated with anti-HER2 sensitivity, chemo-sensitivity and resistance to CDK4/6 inhibition. In the upcoming years, retrospective and prospective clinical trials evaluating both biomarkers should lead to improvements in patient outcomes.